BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17105369)

  • 1. B lymphocytes as therapeutic targets in systemic lupus erythematosus.
    Hasler P; Zouali M
    Expert Opin Ther Targets; 2006 Dec; 10(6):803-15. PubMed ID: 17105369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
    Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
    Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
    Binard A; Le Pottier L; Saraux A; Devauchelle-Pensec V; Pers JO; Youinou P
    J Autoimmun; 2008; 30(1-2):63-7. PubMed ID: 18155417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.
    Fetter T; Niebel D; Braegelmann C; Wenzel J
    Cells; 2020 Dec; 9(12):. PubMed ID: 33297481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLE - Rituximab in lupus.
    Eisenberg R
    Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell depletion therapy in systemic lupus erythematosus.
    Anolik J; Sanz I; Looney RJ
    Curr Rheumatol Rep; 2003 Oct; 5(5):350-6. PubMed ID: 12967516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?
    Stohl W; Looney RJ
    Clin Immunol; 2006 Oct; 121(1):1-12. PubMed ID: 16697258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].
    Valor L; López-Longo FJ
    Med Clin (Barc); 2015 Sep; 145(5):206-10. PubMed ID: 25433780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
    Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
    Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cells as therapeutic targets in SLE.
    Sanz I; Lee FE
    Nat Rev Rheumatol; 2010 Jun; 6(6):326-37. PubMed ID: 20520647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
    Gorman C; Leandro M; Isenberg D
    Lupus; 2004; 13(5):312-6. PubMed ID: 15230284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell biology and related therapies in systemic lupus erythematosus.
    Ahmed S; Anolik JH
    Rheum Dis Clin North Am; 2010 Feb; 36(1):109-30, viii-ix. PubMed ID: 20202594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.